Literature DB >> 16100470

Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis.

Mina Hur1, Young Chul Kim, Kyu Man Lee, Kwang Nam Kim.   

Abstract

Macrophage activation syndrome (MAS) is a rare and potentially fatal complication of rheumatic disorders in children. We describe a 13-month-old boy in whom MAS developed as a complication of systemic juvenile rheumatoid arthritis (S-JRA). He suffered from fever and generalized rash followed by multiple joints swelling for four months before admission. Physical examination revealed cervical lymphadenopathy and hepatosplenomegaly. Laboratory findings were: abnormal liver enzymes, increased triglyceride and ferritin levels, coagulopathies resembling disseminated intravascular coagulation, anemia and thrombocytopenia. Hyperplasia of hemophagocytic macrophages was remarkable in his bone marrow. Methylprednisolone and cyclosporin therapy resulted in clinical and laboratory improvements. This is the third case of MAS associated with S-JRA in Koreans, and the first one, in which hemophagocytic macrophages were proven in bone marrow.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100470      PMCID: PMC2782174          DOI: 10.3346/jkms.2005.20.4.695

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  17 in total

Review 1.  Perforin: more than just an effector molecule.

Authors:  S E Stepp; P A Mathew; M Bennett; G de Saint Basile; V Kumar
Journal:  Immunol Today       Date:  2000-06

Review 2.  Macrophage activation syndrome--what's in a name!

Authors:  Athimalaipet V Ramanan; Rayfel Schneider
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

3.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

Authors:  A Ravelli; F De Benedetti; S Viola; A Martini
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

Review 4.  Systemic onset juvenile rheumatoid arthritis.

Authors:  R Schneider; R M Laxer
Journal:  Baillieres Clin Rheumatol       Date:  1998-05

Review 5.  Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.

Authors:  B E Favara; A C Feller; M Pauli; E S Jaffe; L M Weiss; M Arico; P Bucsky; R M Egeler; G Elinder; H Gadner; M Gresik; J I Henter; S Imashuku; G Janka-Schaub; R Jaffe; S Ladisch; C Nezelof; J Pritchard
Journal:  Med Pediatr Oncol       Date:  1997-09

Review 6.  Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.

Authors:  G Janka; S Imashuku; G Elinder; M Schneider; J I Henter
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

7.  Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.

Authors:  U Emmenegger; U Frey; A Reimers; C Fux; D Semela; P Cottagnoud; P J Spaeth; K A Neftel
Journal:  Am J Hematol       Date:  2001-09       Impact factor: 10.047

8.  Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes.

Authors:  U Emmenegger; R Zehnder; U Frey; A Reimers; P J Spaeth; K A Neftel
Journal:  Am J Hematol       Date:  2000-06       Impact factor: 10.047

9.  Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults.

Authors:  K Akashi; S Hayashi; H Gondo; S Mizuno; M Harada; K Tamura; K Yamasaki; T Shibuya; N Uike; T Okamura
Journal:  Br J Haematol       Date:  1994-06       Impact factor: 6.998

10.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.

Authors:  M Hadchouel; A M Prieur; C Griscelli
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

View more
  4 in total

Review 1.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan Dewitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

2.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

3.  Management of Hepatitis A-induced Macrophage Activation Syndrome With Anakinra in Systemic Juvenile Idiopathic Arthritis: A Case Report.

Authors:  Deena N AlNouwaiser; Sajdi S AlMutairi; Abdullah S AlRowailey
Journal:  Cureus       Date:  2022-01-19

Review 4.  Macrophage activation syndrome: A diagnostic challenge (Review).

Authors:  Anca Bojan; Andrada Parvu; Iulia-Andrea Zsoldos; Tunde Torok; Anca Daniela Farcas
Journal:  Exp Ther Med       Date:  2021-06-24       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.